136 related articles for article (PubMed ID: 19343588)
1. QSAR study of selective I1-imidazoline receptor ligands.
Nikolic K; Filipic S; Agbaba D
SAR QSAR Environ Res; 2009; 20(1-2):133-44. PubMed ID: 19343588
[TBL] [Abstract][Full Text] [Related]
2. QSAR study of imidazoline antihypertensive drugs.
Nikolic K; Filipic S; Agbaba D
Bioorg Med Chem; 2008 Aug; 16(15):7134-40. PubMed ID: 18621536
[TBL] [Abstract][Full Text] [Related]
3. Methylation of imidazoline related compounds leads to loss of α₂-adrenoceptor affinity. Synthesis and biological evaluation of selective I₁ imidazoline receptor ligands.
Schann S; Greney H; Gasparik V; Dontenwill M; Rascente C; Lacroix G; Monassier L; Bruban V; Feldman J; Ehrhardt JD; Bousquet P
Bioorg Med Chem; 2012 Aug; 20(15):4710-5. PubMed ID: 22750139
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F.
Wang XS; Tang H; Golbraikh A; Tropsha A
J Chem Inf Model; 2008 May; 48(5):997-1013. PubMed ID: 18470978
[TBL] [Abstract][Full Text] [Related]
5. Quantitative structure-mobility relationship analysis of imidazoline receptor ligands in CDs-mediated CE.
Filipic S; Nikolic K; Vovk I; Krizman M; Agbaba D
Electrophoresis; 2013 Feb; 34(3):471-82. PubMed ID: 23161743
[TBL] [Abstract][Full Text] [Related]
6. QSAR study of selective ligands for the thyroid hormone receptor beta.
Liu H; Gramatica P
Bioorg Med Chem; 2007 Aug; 15(15):5251-61. PubMed ID: 17524652
[TBL] [Abstract][Full Text] [Related]
7. Prediction of blood-brain barrier permeation of α-adrenergic and imidazoline receptor ligands using PAMPA technique and quantitative-structure permeability relationship analysis.
Vucicevic J; Nikolic K; Dobričić V; Agbaba D
Eur J Pharm Sci; 2015 Feb; 68():94-105. PubMed ID: 25542610
[TBL] [Abstract][Full Text] [Related]
8. QSAR study on melanocortin-4 receptors by support vector machine.
Pourbasheer E; Riahi S; Ganjali MR; Norouzi P
Eur J Med Chem; 2010 Mar; 45(3):1087-93. PubMed ID: 20031282
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
Brogi S; Corelli F; Di Marzo V; Ligresti A; Mugnaini C; Pasquini S; Tafi A
Eur J Med Chem; 2011 Feb; 46(2):547-55. PubMed ID: 21183257
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors.
Shen LL; Liu GX; Tang Y
Acta Pharmacol Sin; 2007 Dec; 28(12):2053-63. PubMed ID: 18031622
[TBL] [Abstract][Full Text] [Related]
11. Affinity prediction on A1 adenosine receptor agonists: the chemometric approach.
Fossa P; Mosti L; Bondavalli F; Schenone S; Ranise A; Casolino C; Forina M
Bioorg Med Chem; 2006 Mar; 14(5):1348-63. PubMed ID: 16263293
[TBL] [Abstract][Full Text] [Related]
12. Molecular modeling and structure-activity relationship of podophyllotoxin and its congeners.
Naik PK; Alam A; Malhotra A; Rizvi O
J Biomol Screen; 2010 Jun; 15(5):528-40. PubMed ID: 20460251
[TBL] [Abstract][Full Text] [Related]
13. QSAR analysis of salicylamide isosteres with the use of quantum chemical molecular descriptors.
Dolezal R; Van Damme S; Bultinck P; Waisser K
Eur J Med Chem; 2009 Feb; 44(2):869-76. PubMed ID: 18547684
[TBL] [Abstract][Full Text] [Related]
14. QSAR analyses of 3-(4-benzylpiperidin-1-yl)-N-phenylpropylamine derivatives as potent CCR5 antagonists.
Roy K; Leonard JT
J Chem Inf Model; 2005; 45(5):1352-68. PubMed ID: 16180912
[TBL] [Abstract][Full Text] [Related]
15. A DFT-based quantum theoretic QSAR study of aromatic and heterocyclic sulfonamides as carbonic anhydrase inhibitors against isozyme, CA-II.
Eroglu E; Türkmen H
J Mol Graph Model; 2007 Nov; 26(4):701-8. PubMed ID: 17493855
[TBL] [Abstract][Full Text] [Related]
16. Exploring QSAR of peripheral benzodiazepine receptor binding affinity of N,N-dialkyl-2-phenylindol-3-yl-glyoxylamides using physico-chemical descriptors.
Roy K; Dalai MK
Indian J Biochem Biophys; 2007 Apr; 44(2):114-21. PubMed ID: 17536340
[TBL] [Abstract][Full Text] [Related]
17. Behavioral involvement of imidazoline system.
Nechifor M; Ciubotariu D
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):552-6. PubMed ID: 23077952
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands.
Boronat MA; Olmos G; García-Sevilla JA
Br J Pharmacol; 1998 Sep; 125(1):175-85. PubMed ID: 9776358
[TBL] [Abstract][Full Text] [Related]
19. Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR.
Vedani A; Dobler M; Dollinger H; Hasselbach KM; Birke F; Lill MA
J Med Chem; 2005 Mar; 48(5):1515-27. PubMed ID: 15743194
[TBL] [Abstract][Full Text] [Related]
20. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
Salum Lde B; Polikarpov I; Andricopulo AD
J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
